IMMUNOLOGY2026™ Conference Recordings For Attendees-Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development, Sponsored by Breakthrough T1D

Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development, Sponsored by Breakthrough T1D

Video Transcription

Video Summary

Dr. Tyler Jenkins described AKS107, an insulin-specific immunotherapy designed to selectively deplete anti-insulin B cells in type 1 diabetes while sparing other B cells. In NOD and VH125 NOD mice, AKS107 significantly reduced anti-insulin B cells in the spleen, pancreatic lymph nodes, and pancreas, with stronger effects after longer, chronic dosing. It also lowered insulitis, or immune-cell infiltration of pancreatic islets. However, a control antigen showed some similar effects on insulitis, suggesting more study is needed. Overall, the work supports antigen-specific immunotherapy as a more targeted potential treatment for type 1 diabetes.

Meta Tag

Date April 16, 2026 7:00 AM - 8:00 AM

Room 151

Session Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development

Speaker Tyler Jenkins

Track Basic Autoimmunity (BA)

Year 2026

Keywords

AKS107

type 1 diabetes

anti-insulin B cells

antigen-specific immunotherapy

insulitis

April 16, 2026 7:00 AM - 8:00 AM

151

Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development

Tyler Jenkins

Basic Autoimmunity (BA)

2026